Breast, Cambria-2 D8535C00001

This is a Phase III open-label study to assess if camizestrant improves outcomes compared to standard adjuvant endocrine therapy for patients with ER+/HER2- early breast cancer with intermediate-high or high risk for disease recurrence who completed definitive locoregional therapy (with or without chemotherapy).

Breast, OptimICE-pCR: A012103

This phase III trial compares the effect of pembrolizumab to observation for the treatment of patients with early-stage triple-negative breast cancer who achieved a pathologic complete response after preoperative chemotherapy in combination with pembrolizumab.

Pamela Coffey Discusses Dealing with Cancer during the Holidays

Pamela Coffey is a Licensed Clinical Social Worker who works with cancer patients and their families at Hematology-Oncology Associat

Patient Newsletter 2023 December

Advocacy Update on Seniors' Access to Critical Medications

Problem/Issue:
In September 2021, the Centers for Medicare & Medicaid Services (CMS) published a Frequently Asked Questions document (FAQ) prohibiting physicians from delivering oral cancer drugs and other medications to their patients by mail, FedEx, UPS, courier, or other means. CMS’ FAQ also prohibits a spouse, family member, or caregiver from picking up medication on a patient’s behalf.

All About Cancer Genetics Testing

Patient Newsletter 2023 November

Lung Cancer Awareness Month with Dr. Kavitha Prezzano, Radiation Oncologist at HOA

Dr. Kavitha Prezzano discusses Lung Cancer Awareness Month on our Bridge Street segment "Cancer Q&A with HOA."

Patient Newsletter 2023 October

FREE Lung Cancer Screening Saturday, Nov. 4, 2023

Pages